GLPwatch
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
NCT03757130 · Completed
Last updated 2026-05-28This clinical trial tests the safety of different doses of the drug AMG 598 in adults who have obesity.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind study
Participants 50 people
Who can join Ages 18–65 · all sexes
Timeline Started 2018-11 · est. completion 2019-12
Where 4 sites · United States
What this study is testing ClinicalTrials.gov NCT03757130 ↗
Description as written by the study sponsor.
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
Treatments tested
- AMG 598 Drug
AMG 598 administered by subcutaneous injection
- Placebo Drug
Placebo matching to AMG 598 administered by subcutaneous injection
- Liraglutide also known as Saxenda® Drug
Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
| Main thing measured | Number of Participants With Treatment-emergent Adverse Events |
|---|---|
| Sponsor | Amgen |
| Conditions studied | Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03757130 ↗